<DOC>
	<DOCNO>NCT01858103</DOCNO>
	<brief_summary>The Expanded Access Program ( EAP ) open-label , multicenter program : 1 . Provide patient diagnosed Mucopolysaccharidosis IVA ( MPS IVA ) access BMN 110 commercial product available 2 . Collect additional information safety tolerability BMN 110 administration patient MPS IVA Patients enrol EAP receive 2.0 mg/kg intravenous infusion BMN 110 every week program .</brief_summary>
	<brief_title>BMN 110 US Expanded Access Program</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis IV</mesh_term>
	<criteria>Diagnosed MPS IVA confirm either Nacetylgalactosamine6sulfatase ( GALNS ) enzymatic test ( GALNS activity affect range , betagalactosidase second lysosomal sulfatase activity within normal range ) molecular diagnostic test ( two mutation GALNS identify previously associate enzyme defect ) . Willing able provide write , sign informed consent , case patient age 18 , provide write assent ( required IRB ) write informed consent legally authorize representative nature program explain , prior program assessment evaluation . Sexually active patient must willing use acceptable method contraception participate program . Females childbearing potential must negative pregnancy test Baseline willing additional pregnancy test program . Willing able comply program procedure . Pregnant breastfeed Baseline planning become pregnant ( self partner ) time program . Patients become pregnant program discontinue program . Currently enrol ongoing clinical study BMN 110 . Discontinued BMN 110 clinical study secondary safetyrelated event . Use investigational product ( BMN 110 clinical study ) investigational medical device within 30 day prior Baseline , requirement investigational agent prior completion schedule program assessment . Not current US resident expect travel plan outside US plan period participation Expanded Access Program ( EAP ) may interfere dose regimen , schedule program visit safety monitoring . Any condition , view Investigator sponsor , place patient high risk poor treatment compliance complete EAP .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Mucopolysaccharidosis IVA Type A</keyword>
	<keyword>MPS IVA Type A</keyword>
	<keyword>Mucopolysaccharidosis IVA</keyword>
	<keyword>MPS IVA</keyword>
	<keyword>Morquio A Syndrome</keyword>
	<keyword>Lysosomal Storage Disorder</keyword>
	<keyword>LSD</keyword>
	<keyword>N-acetylgalactosamine-6-sulfatase</keyword>
	<keyword>N-acetylgalactosamine-6-sulfate</keyword>
</DOC>